Creekmur Asset Management LLC Acquires 8,010 Shares of Novo Nordisk A/S (NYSE:NVO)

Creekmur Asset Management LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 784.5% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 9,031 shares of the company's stock after purchasing an additional 8,010 shares during the period. Creekmur Asset Management LLC's holdings in Novo Nordisk A/S were worth $627,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in NVO. Strategic Investment Solutions Inc. IL lifted its holdings in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares during the last quarter. Copeland Capital Management LLC increased its position in Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after buying an additional 255 shares during the period. North Capital Inc. acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth $27,000. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $29,000. Finally, Transce3nd LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at about $33,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. BMO Capital Markets restated a "market perform" rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. BNP Paribas started coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and a consensus target price of $112.00.

Novo Nordisk A/S Trading Down 1.5%

NYSE NVO traded down $0.97 on Friday, hitting $64.32. The company's stock had a trading volume of 8,032,293 shares, compared to its average volume of 7,363,987. The company's 50-day moving average is $70.37 and its 200 day moving average is $74.53. The firm has a market cap of $287.19 billion, a PE ratio of 19.03, a PEG ratio of 1.26 and a beta of 0.64. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $139.74. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. As a group, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.